Angewandte Chemie International Edition,
Journal Year:
2022,
Volume and Issue:
61(14)
Published: Jan. 6, 2022
Abstract
The
impermeable
barriers
of
solid
tumors
restrict
the
co‐delivery
protein‐based
drugs
and
chemotherapeutics
for
cancer
treatment.
Therefore,
we
developed
a
ZIF‐DOX/RA@DG
nanosystem
that
encapsulates
ribonuclease
A
(RA)
doxorubicin
(DOX)
in
zeolitic
imidazolate
framework
(ZIF‐8)
core,
with
dextran‐based
coating
(DG).
exhibits
dual‐responsiveness
due
to
γ‐glutamyl
transpeptidase‐activatable
cationization
acidic
microenvironment‐triggered
degradation.
DG‐coating
process
was
achieved
using
microfluidic
approach,
which
stabilized
polymer
responsiveness,
ZIF‐8‐based
structure,
bioactivity
encapsulated
therapeutics.
In
vivo
results
confirmed
could
co‐deliver
RA
DOX
deep
lesions
synergistic
anticancer
therapeutic
effects.
Such
multi‐drug
delivery
system
based
on
an
intelligent‐responsive
design
microfluidics‐assisted
synthesis
strategy
shows
great
clinical
prospects.
Small,
Journal Year:
2022,
Volume and Issue:
18(26)
Published: June 3, 2022
Abstract
Sonodynamic
therapy
(SDT)
is
garnering
considerable
attention
in
cancer
treatment
due
to
its
non‐invasive
nature
and
the
potential
of
spatiotemporal
control.
However,
high
level
glutathione
(GSH)
cells
can
alleviate
SDT‐mediated
ROS‐damages,
resulting
a
reduced
SDT
effect.
Here,
two‐in‐one
nano‐prodrug
for
photoacoustic
imaging‐guided
enhanced
against
skin
cancers
synthesized.
A
dual‐prodrug
molecule
(DOA)
sulfide
dioxide
(SO
2
)
5‐aminolevulinic
acid
(ALA)
first
synthesized
then
co‐assembled
with
methoxyl
poly(ethylene
glycol)‐
b
‐poly(
l
‐lysine)
(mPEG‐
‐PLL)
generate
prodrug
nanoparticles
(P‐DOA
NPs).
The
P‐DOA
NPs
simultaneously
released
ALA
SO
response
overexpressed
GSH
tumor
cells.
metabolically
converted
into
protoporphyrin
IX
(PpIX)
imaging.
Meanwhile,
,
together
consumption
based
on
reaction
DOA
intracellular
GSH,
significantly
increase
ROS
content,
leading
SDT.
As
result,
inhibited
growth
melanoma
squamous
cell
carcinoma
xenografts
mouse
models
under
guidance
real‐time
Therefore,
this
novel
promising
effective
cancers.
Angewandte Chemie International Edition,
Journal Year:
2022,
Volume and Issue:
61(14)
Published: Jan. 6, 2022
Abstract
The
impermeable
barriers
of
solid
tumors
restrict
the
co‐delivery
protein‐based
drugs
and
chemotherapeutics
for
cancer
treatment.
Therefore,
we
developed
a
ZIF‐DOX/RA@DG
nanosystem
that
encapsulates
ribonuclease
A
(RA)
doxorubicin
(DOX)
in
zeolitic
imidazolate
framework
(ZIF‐8)
core,
with
dextran‐based
coating
(DG).
exhibits
dual‐responsiveness
due
to
γ‐glutamyl
transpeptidase‐activatable
cationization
acidic
microenvironment‐triggered
degradation.
DG‐coating
process
was
achieved
using
microfluidic
approach,
which
stabilized
polymer
responsiveness,
ZIF‐8‐based
structure,
bioactivity
encapsulated
therapeutics.
In
vivo
results
confirmed
could
co‐deliver
RA
DOX
deep
lesions
synergistic
anticancer
therapeutic
effects.
Such
multi‐drug
delivery
system
based
on
an
intelligent‐responsive
design
microfluidics‐assisted
synthesis
strategy
shows
great
clinical
prospects.
